{
    "1": {
        "question": "What main advantage does the SeC@PA microneedle bandage offer over traditional topical applications for diabetic wounds?",
        "options": [
            "A. It enhances the delivery of antibiotics directly into the blood.",
            "B. It bypasses the acidic environment of the stomach.",
            "C. It delivers therapeutic agents directly to the wound tissues beneath biofilms.",
            "D. It requires oral administration for systemic effect.",
            "E. It increases the temperature of the wound site to control infection.",
            "F. I don't know."
        ]
    },
    "2": {
        "question": "What role does selenium (Se) play in the therapeutic design of the SeC@PA microneedles?",
        "options": [
            "A. It accelerates the proliferation of pathogenic bacteria.",
            "B. It acts as a photosensitizing agent.",
            "C. It helps in the polarization of macrophages to the M1 phenotype.",
            "D. It participates in the generation of reactive species to eradicate biofilms.",
            "E. It binds to toxins released by bacteria.",
            "F. I don't know."
        ]
    },
    "3": {
        "question": "How does SeC@PA regulate reactive species (RS) in different microenvironments?",
        "options": [
            "A. It increases RS only when glucose levels are high.",
            "B. It amplifies RS at low GSH levels and reduces at high GSH levels.",
            "C. It decreases RS generation when the pH drops below 4.",
            "D. It amplifies RS in high GSH environments and scavenges them in low GSH environments.",
            "E. It solely acts as an RS generator irrespective of the microenvironment.",
            "F. I don't know."
        ]
    },
    "4": {
        "question": "What is the primary function of chlorin e6 (Ce6) in the SeC@PA formulation?",
        "options": [
            "A. Enhancing the thermal conductive properties of the wound.",
            "B. Acting as a photosensitizer for generating reactive oxygen species.",
            "C. Increasing the structural rigidity of the microneedle bandage.",
            "D. Stabilizing the nanoparticles' structure under different temperatures.",
            "E. Neutralizing nitric oxide within the biological tissues.",
            "F. I don't know."
        ]
    },
    "5": {
        "question": "Based on the results shown in Fig. 3, which treatment exhibits the strongest anti-biofilm activity?",
        "options": [
            "A. Control group",
            "B. Se@PA group",
            "C. C@P(+) group",
            "D. SeC@PA(+) group",
            "E. SeR@PA NPs",
            "F. I don't know."
        ]
    },
    "6": {
        "question": "What is the function of L-arginine (LA) when modified on the surface of SeC@PA nanoparticles?",
        "options": [
            "A. To lower the immunogenic response to the nanoparticles.",
            "B. To produce nitric oxide for glutathione depletion and reactive nitrogen species (RNS) formation.",
            "C. To enhance adhesion of the bandage to the skin surface.",
            "D. To increase nanoparticle solubility in hydrophobic media.",
            "E. To act as a lubricant during microneedle application.",
            "F. I don't know."
        ]
    },
    "7": {
        "question": "In the context of wound treatments in diabetic mice, what was the observed effect of the SeC@PA MN bandage?",
        "options": [
            "A. It slowed wound closure significantly compared to controls.",
            "B. It had no significant influence on wound healing rates.",
            "C. It accelerated wound healing effectively with high collagen deposition.",
            "D. It resulted in increased wound infection rates.",
            "E. It increased systemic levels of inflammatory cytokines.",
            "F. I don't know."
        ]
    },
    "8": {
        "question": "What histological changes were observed in wounds treated with SeC@PA MN(+) as evident in Fig. 6?",
        "options": [
            "A. More irregular skin structure and decreased collagen deposition.",
            "B. Decreased blood vessel density.",
            "C. Enhanced collagen deposition and increased blood vessel density.",
            "D. Increased bacterial colony formation.",
            "E. Decreased epidermis and dermis integrity.",
            "F. I don't know."
        ]
    },
    "9": {
        "question": "In Figure 2, how does the NO production correlate with irradiation intensity and concentration of SeC@PA?",
        "options": [
            "A. NO production decreases with increased irradiation intensity.",
            "B. NO production increases with higher concentrations of SeC@PA and stronger irradiation.",
            "C. NO production is unaffected by changes in irradiation or concentrations.",
            "D. NO is not detected at any level of irradiation or concentration.",
            "E. NO production diminishes with higher concentrations of SeC@PA.",
            "F. I don't know."
        ]
    },
    "10": {
        "question": "What distinguishes the SeC@PA microneedle bandage from SeC@PA nanoparticles (NPs) regarding biofilm penetration, as shown in Fig. 7?",
        "options": [
            "A. Both show equivalent penetration.",
            "B. NPs penetrate biofilms more effectively than MNs.",
            "C. MNs penetrate significantly deeper into biofilms than NPs.",
            "D. NPs are able to deliver drug into the bloodstream directly.",
            "E. MNs have no measurable effect on penetration.",
            "F. I don't know."
        ]
    },
    "11": {
        "question": "According to Table [1], what is the approximate hydrodynamic diameter of SeC@PA nanoparticles?",
        "options": [
            "A. 38.42 nm",
            "B. 54.73 nm",
            "C. 108.47 nm",
            "D. 90.00 nm",
            "E. 100 nm",
            "F. I don't know."
        ]
    },
    "12": {
        "question": "What is the primary benefit of selenium's interaction with glutathione (GSH) in SeC@PA's function?",
        "options": [
            "A. It prevents selenium from degrading.",
            "B. It promotes inflammatory cytokine production.",
            "C. It allows SeC@PA to produce reactive species by decomposing GSH.",
            "D. It neutralizes the antimicrobial properties of selenium.",
            "E. It reduces selenium's oxidative activity.",
            "F. I don't know."
        ]
    },
    "13": {
        "question": "How does the presence of biofilms on diabetic wounds affect the application of SeC@PA treatments?",
        "options": [
            "A. It has no effect; treatments work equally well regardless of biofilms.",
            "B. It enhances the delivery of therapeutic agents into the bloodstream.",
            "C. Biofilms form a barrier that reduces the efficacy of topical agents without MNs.",
            "D. Biofilms facilitate treatment absorption, accelerating healing.",
            "E. The treatment induces increased biofilm formation.",
            "F. I don't know."
        ]
    },
    "14": {
        "question": "Through which pathway does SeC@PA stimulate macrophage polarization to the M2 phenotype as noted in the article?",
        "options": [
            "A. PI3K-AKT pathway",
            "B. JAK-STAT6 pathway",
            "C. MAPK-ERK pathway",
            "D. NF-kB pathway",
            "E. TLR4 pathway",
            "F. I don't know."
        ]
    },
    "15": {
        "question": "What was the effect of SeC@PA MN on inflammation as detailed under Figure 10 in the study?",
        "options": [
            "A. Increased levels of pro-inflammatory cytokines.",
            "B. Reduced M2 macrophage infiltration.",
            "C. Promoted polarization of macrophages to the anti-inflammatory M2 phenotype.",
            "D. Initiated acute inflammation response in healthy tissues.",
            "E. Halved the number of infiltrating immune cells.",
            "F. I don't know."
        ]
    },
    "16": {
        "question": "What evidence is presented to show that SeC@PA treatment improves angiogenesis in wound sites?",
        "options": [
            "A. Reduced collagen deposition was observed.",
            "B. Enhanced expression levels of IL-1 and TNF-\u03b1.",
            "C. Increased CD31 staining indicating more blood vessels.",
            "D. Disrupted blood vessel formation.",
            "E. Unaltered CD206 levels in macrophages.",
            "F. I don't know."
        ]
    },
    "17": {
        "question": "What change was reported in GSH levels in wound coverings treated with SeC@PA MN according to Supplementary Fig. 28?",
        "options": [
            "A. No change in GSH levels.",
            "B. Increased GSH levels in the wound tissue.",
            "C. Decreased GSH levels in wound coverings.",
            "D. GSH levels were significantly higher in wound coverings compared to tissue.",
            "E. GSH levels dropped to zero in all cases.",
            "F. I don't know."
        ]
    },
    "18": {
        "question": "How does the application of SeC@PA (+) MN affect wound RS levels?",
        "options": [
            "A. Increases RS levels, causing more oxidative stress.",
            "B. Has no significant effect on RS levels.",
            "C. Reduces RS levels, demonstrating scavenging effects.",
            "D. Boosts DNA damage in surrounding cells.",
            "E. Inhibits all cellular functions due to high RS.",
            "F. I don't know."
        ]
    },
    "19": {
        "question": "What key factor allows SeC@PA microneedles to independently regulate reactive species at wound sites?",
        "options": [
            "A. A temperature-dependent reaction rate.",
            "B. External addition of buffering agents.",
            "C. The presence of high levels of glucose.",
            "D. The ability to sense different levels of glutathione (GSH).",
            "E. Constant mechanical agitation during the treatment period.",
            "F. I don't know."
        ]
    },
    "20": {
        "question": "What was the outcome of using Se@PA MN in diabetic wounds without biofilms compared to other treatments?",
        "options": [
            "A. Resulted in slower wound healing due to increased RS.",
            "B. Showed reduced inflammation and enhanced healing compared to C@PA MN(+).",
            "C. Underperformed in healing compared to control MN.",
            "D. Stimulated higher rates of infection.",
            "E. Increased systemic toxicity.",
            "F. I don't know."
        ]
    }
}